Bausch Health (BHC) is expected to post Q1 revenue of $2.24 billion, shy of the $2.29 billion estimate of analysts polled by FactSet, RBC Capital Markets said in an earnings preview Monday.
RBC analysts also said they expect the pharmaceutical company to report Q1 adjusted EBITDA of $720 million while analysts surveyed by FactSet expect $769.8 million.
The investment firm said it revised its Q1 estimates due to foreign exchange movements and updated prescription data. Regarding tariffs, RBC analysts said they plan to seek updated comments from management on the potential impact to the company. Previously, Bausch Health's management said they were forecasting an impact of less than $500 million to cash flow under a 25% tariff rate.
Bausch Health is due to report Q1 results after the close on April 30.
RBC cut its price target to $8.50 from $9 and kept a sector perform rating on the stock.
Price: 5.09, Change: -0.25, Percent Change: -4.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。